2026 Oncology Institute
August 12, 2026 | 12:00 PM EST
Upcoming Webinar
Optimizing Testing and Treatment in ROS1+ NSCLC: Applying NCCN Guidelines® and Reviewing Clinical Data for taletrectinib (Ibtrozi™)
Date: October 22, 2025 | 2:00 PM
When: Tuesday, October 22 | 2 p.m. EST
Presenter: Anna Markel Vaysman, PharmD, BCPS | Nuvation Bio
In oncology, precision matters—and for patients with ROS1+ NSCLC, testing and treatment alignment can be the difference between access and delay, progress and frustration. This session brings a clear, practical look at how care teams can make these decisions easier, smarter, and more consistent across every practice setting.
What to expect:
- A focused look at how the latest NCCN Guidelines® shape biomarker testing and ROS1-targeted therapy selection.
- Real talk about the gaps and challenges community oncology teams face in testing consistency and treatment coordination.
- An in-depth review of clinical data for taletrectinib (Ibtrozi™)—including efficacy, safety, and its potential role in today’s treatment landscape.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars

October 23, 2025 | 2:00 PM

October 27, 2025 | 2:00 PM

Upcoming Webinar
Pharmacy Perspectives: Bringing Bispecifics and 505(b)(2) Medications Into Practice
October 28, 2025 | 5:00 PM